Mersana Therapeutics Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Cambridge, Massachusetts and currently employs 102 full-time employees. The company went IPO on 2017-06-28. Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is focused on the development of antibody-drug conjugates (ADCs), which offer a clinically meaningful benefit for cancer patients with significant unmet needs. The company has developed two proprietary and differentiated ADC platforms: Dolasynthen and Immunosynthen. Dolasynthen is a cytotoxic ADC platform that is designed to generate site-specific, homogeneous ADCs. Immunosynthen is its proprietary stimulator of interferon genes (STING)-agonist platform that is designed to generate systemically administered ADCs that locally activate STING signaling in both antigen-expressing tumor cells and in tumor-resident immune cells. The firm's pipeline includes Emi-Le (emiltatug ledadotin; XMT-1660), a Dolasynthen ADC targeting B7-H4, and XMT-2056, an Immunosynthen ADC targeting a novel epitope of human epidermal growth factor receptor 2 (HER2).
Follow-Up Questions
Who is the CEO of Mersana Therapeutics Inc?
Dr. Martin Huber is the President of Mersana Therapeutics Inc, joining the firm since 2020.
What is the price performance of MRSN stock?
The current price of MRSN is $8.45, it has decreased 0% in the last trading day.
What are the primary business themes or industries for Mersana Therapeutics Inc?
Mersana Therapeutics Inc belongs to Biotechnology industry and the sector is Health Care
What is Mersana Therapeutics Inc market cap?
Mersana Therapeutics Inc's current market cap is $42.1M
Is Mersana Therapeutics Inc a buy, sell, or hold?
According to wall street analysts, 9 analysts have made analyst ratings for Mersana Therapeutics Inc, including 7 strong buy, 6 buy, 2 hold, 0 sell, and 7 strong sell
